Core Viewpoint - The company, Zhongke Meiling Cryogenic Technology Co., Ltd., is utilizing idle funds for cash management, with a maximum investment of 260 million RMB in bank financial products while ensuring operational liquidity and risk control [1] Group 1: Financial Management - The company announced the use of 110 million RMB of idle self-owned funds for cash management, with a remaining balance of 230 million RMB in self-owned financial products [1] - The maximum amount for investment in bank financial products is set at 260 million RMB [1] Group 2: Company Overview - Zhongke Meiling was established in 2002 in Hefei, Anhui Province, and is one of the early entrants in the biological cell ultra-low temperature storage sector [1] - The company specializes in the research, production, and sales of a wide range of low-temperature storage equipment and provides comprehensive solutions in the biomedical field [1] Group 3: Achievements and Recognition - The company is recognized as a high-tech enterprise and a national-level "specialized and innovative" small giant enterprise, receiving numerous awards including the National Technology Invention Award (second prize) and various provincial and municipal honors [2] - The company aims to enhance its core refrigeration technology in the biomedical field and accelerate domestic substitution efforts [2] Group 4: Performance Metrics - In the first three quarters of 2025, the company achieved operating revenue of 224 million RMB, representing a year-on-year growth of 4.75%, and a net profit attributable to shareholders of 12.76 million RMB, with an increase of 8.19% year-on-year [3]
中科美菱（920992）使用1.1亿元的自有资金购买理财产品 提高自有资金使用效率